This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BioPharm America
2 days in-person. 2 days virtually.
September 28–29, 2022 | Boston, USAOctober 4–5, 2022 | Virtual

Safi Biotherapeutics


Safi Biotherapeutics is a pre-clinical stage cell therapy company applying proprietary technologies for in vitro production of allogeneic blood cells at unprecedented scale and with viable economics for multi-unit transfusions.

  • Manufactured Red Blood Cells (mRBC) - With active blood donating populations steadily decreasing, and pandemics further exacerbating bloody supply challenges, Safi Bio is developing a specific-phenotype, manufactured red blood cell (mRBC) for chronic transfusion patients at high risk of alloimmunization where alternatives to donor RBC supply are needed. Indications with unmet needs include hemoglobinopathies, such as Sickle Cell Disease and Beta Thalessemia, and post-chemotherapy anemia.
  • mRBC Drug-loading/Delivery platform - Safi Bio has conducted initial POC studies to establish the benefits of our fully enucleated mRBCs as an effective in vivo drug delivery system. These studies demonstrate efficient drug loading and cryopreservation of Safi mRBCs using two effective—but otherwise highly toxic—approved pharmaceuticals.
  • Neutrophil Progenitor Cells (NPC) - Safi Bio is partnering with researchers at Massachusetts General Hospital (MGH) to apply a novel cell immortalization technology to produce cryopreservable Neutrophil Progenitor Cells (NPCs) as a more effective treatment for severe neutropenia following chemotherapy or radiation exposure (an increasing concern as risks of radiological events are heightened around the world).